|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
After adjusting for known risk loci, rs2736100 and rs401681, we identified a new, independent lung cancer susceptibility variant in LPCAT1: rs139852726 (OR = 0.46, P = 4.73×10(-9)), and three new adenocarcinoma risk variants in TERT: rs61748181 (OR = 0.53, P = 2.64×10(-6)), rs112290073 (OR = 1.85, P = 1.27×10(-5)), rs138895564 (OR = 2.16, P = 2.06×10(-5); among young cases, OR = 3.77, P = 8.41×10(-4)).
|
26590902 |
2016 |
|
Malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
After adjusting for known risk loci, rs2736100 and rs401681, we identified a new, independent lung cancer susceptibility variant in LPCAT1: rs139852726 (OR = 0.46, P = 4.73×10(-9)), and three new adenocarcinoma risk variants in TERT: rs61748181 (OR = 0.53, P = 2.64×10(-6)), rs112290073 (OR = 1.85, P = 1.27×10(-5)), rs138895564 (OR = 2.16, P = 2.06×10(-5); among young cases, OR = 3.77, P = 8.41×10(-4)).
|
26590902 |
2016 |
|
Carcinoma of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
After adjusting for known risk loci, rs2736100 and rs401681, we identified a new, independent lung cancer susceptibility variant in LPCAT1: rs139852726 (OR = 0.46, P = 4.73×10(-9)), and three new adenocarcinoma risk variants in TERT: rs61748181 (OR = 0.53, P = 2.64×10(-6)), rs112290073 (OR = 1.85, P = 1.27×10(-5)), rs138895564 (OR = 2.16, P = 2.06×10(-5); among young cases, OR = 3.77, P = 8.41×10(-4)).
|
26590902 |
2016 |
|
Adenocarcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
After adjusting for known risk loci, rs2736100 and rs401681, we identified a new, independent lung cancer susceptibility variant in LPCAT1: rs139852726 (OR = 0.46, P = 4.73×10(-9)), and three new adenocarcinoma risk variants in TERT: rs61748181 (OR = 0.53, P = 2.64×10(-6)), rs112290073 (OR = 1.85, P = 1.27×10(-5)), rs138895564 (OR = 2.16, P = 2.06×10(-5); among young cases, OR = 3.77, P = 8.41×10(-4)).
|
26590902 |
2016 |
|
Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Telomerase variant A279T induces telomere dysfunction and inhibits non-canonical telomerase activity in esophageal carcinomas.
|
24983628 |
2014 |
|
Esophageal carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
A279T induces telomere dysfunction and inhibits non-canonical telomerase activity in esophageal cancer cells.
|
24983628 |
2014 |
|
Esophageal Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
A279T induces telomere dysfunction and inhibits non-canonical telomerase activity in esophageal cancer cells.
|
24983628 |
2014 |
|
Congenital chromosomal disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
A279T expression significantly increased chromosomal aberrations in mouse embryonic fibroblasts (MEFs) following Zeocin™ exposure, as well as Li Fraumeni fibroblasts in the absence of pharmacologically-induced DNA damage.
|
24983628 |
2014 |
|
Malignant neoplasm of esophagus
|
|
0.010 |
GeneticVariation
|
BEFREE |
These findings warrant further analysis of A279T expression in esophageal cancers and premalignant esophageal lesions.
|
24983628 |
2014 |
|
Precancerous Conditions
|
|
0.010 |
GeneticVariation
|
BEFREE |
These findings warrant further analysis of A279T expression in esophageal cancers and premalignant esophageal lesions.
|
24983628 |
2014 |